Bulbous buttercup

Bulbous Buttercup (Ranunculus bulbosus L.): A Comprehensive Reference

1. Identity and Botanical Description

Nomenclature and Taxonomy

Bulbous buttercup (Ranunculus bulbosus), commonly known as bulbous buttercup or St. Anthony's turnip, is a perennial flowering plant in the buttercup family Ranunculaceae. The species was formally named and described by Carl Linnaeus in his seminal work Species Plantarum in 1753, under the Ranunculaceae family. The genus name carries significant etymological meaning: the name "Ranunculus" comes from the Latin word ranunculus, meaning "little frog," likely referring to the plant's preference for wet environments. Although the presence of a corm distinguishes Ranunculus bulbosus from some other species of buttercup such as Ranunculus acris, the species also has distinctive reflexed sepals. Other names for the bulbous buttercup are "Goldcup," because of the colour and shape of the flowers, and "Frogs-foot," from the form of its leaves.

Synonyms and common names include: anemonic acid, anemonin, bachelor's buttons, bachelor's cheese, blister flower, blister plant, blister weed, bouton d'or (French), bulbous crowfoot, burrwort, butter and cheese, buttercup, butter flower, butterrose, common buttercup, crazy weed, crazyweed, crowfoot, frogsfoot, giltcup, goldcup, goldknob, gowan, jaunet (French), meadow bloom, meadow buttercup, protoanemonin, St. Anthony's rape, St. Anthony's turnip, tall crowfoot, tall field buttercup, and upright meadow crowfoot.

Morphology and Growth Habit

The stems are 20–40 cm (8–16 in) tall, erect, branching, and slightly hairy, with a swollen corm-like base. The flower forms at the apex of the stems, with 5–7 petals, the sepals strongly reflexed. The flowers are glossy yellow and 1.5–3 cm (0.6–1.2 in) wide. The plant blooms from April to July.

The bulbous buttercup gets its name from its distinctive perennating organ — a bulb-like swollen underground stem or corm — which is situated just below the soil surface. After the plant dies in the heat of summer, the corm survives underground through the winter.

Native Range and Habitat

The native range of Ranunculus bulbosus is Western Europe, between about 60°N and the Northern Mediterranean coast. It grows in both the eastern and western parts of North America as an introduced weed. Bulbous buttercup grows in lawns, pastures, and fields in general, preferring nutrient-poor, well-drained soils.

2. Common Forms and Preparations

Bulbous buttercup contains acrid, harsh chemicals that cause uncomfortable and severe reactions wherever it comes into contact with the body. Because of this, bulbous buttercup is not a frequently used herbal plant today. All parts of the bulbous buttercup are now known to be poisonous. The active properties of bulbous buttercup are thought to be destroyed upon heating or drying.

Preparations that have been described historically and within the homeopathic tradition include:

• Mother tincture (Q): Its action came into homeopathic use after the proving done by Dr. Franz. The medicine is prepared from the whole plant.
• Potentized homeopathic remedies: The whole plant is used to extract the medicine, which undergoes potentization — the process of preparing homeopathic medicines that extract and intensifies the medicinal properties from a crude substance — to obtain the homeopathic remedy Ranunculus Bulbosus.
• Hydroalcoholic and glycerol-ethanol extracts: Modern analytical studies have evaluated two types of extracts — hydroalcoholic (HA) and glycerol-ethanol (GE) — for their content of active constituents.
• Dried and cooked corm: The root must be dried beforehand and thoroughly cooked before any use as food. When boiled, the roots are said to become so mild as to be edible.

3. Traditional and Historical Use

Ancient and Classical Antiquity

Prior to Linnaeus, buttercups in the genus, including forms resembling R. bulbosus, appear in ancient Roman texts by Pliny the Elder and medieval European herbals, where they were noted for medicinal properties despite their toxicity. The Italian naturalist Pliny the Elder wrote about the beneficial uses of ranunculus in "The Natural History of Wild Plants" as early as 77 B.C.E.

European Folk and Herbal Medicine

Historically, the plant was used for external applications to treat skin conditions such as blisters, shingles, and corns. In the ethnobotanical record, R. bulbosus is indicated as a remedy for neuralgia pains, as an anti-spasmodic, and as a diaphoretic. European folk traditions also employed it externally as a counterirritant — applying the acrid fresh plant to the skin to raise blisters that were believed to draw out disease. Several Ranunculus species have been used in folk medicine to treat various diseases or symptoms, such as jaundice, nebula, edema, malaria, asthma, pain, gout, rheumatism, inflammatory skin disorders, cancer, and hypertension.

The caustic and pain-producing properties of the Ranunculaceae reach their highest expression in the buttercups themselves. R. bulbosus forms a constituent of some arsenical plasters used historically to disperse cancers.

In the context of famine foods, R. bulbosus has bulbous roots that are toxic when fresh but are said to be edible after they are well boiled or completely dried.

Native American and North American Use

Native Americans used the dried Ranunculus plant in herbal poultices to treat muscle aches and pains and to remove warts.

Homeopathic Tradition (19th–20th Centuries)

R. bulbosus was proved by Franz, and some effects of its external application were observed, including results of inhaling the fumes whilst preparing the plant or when it was burned. Within the classical homeopathic materia medica, the plant was assigned a broad sphere of application. The sphere of action of Ranunculus bulbosus in homeopathic practice is described as chiefly affecting the mind, respiratory system, skin, and extremities. Key homeopathic indications documented in classical materia medica texts include chest pain, intercostal neuralgia, herpes zoster, delirium tremens, rheumatism, sciatica, writer's cramp, and corns. The homeopathic tincture of the whole plant was used clinically for alcoholism, breast pain, chest pains, chilblains, and corns, among many other indications.

It bears emphasis that homeopathic use is grounded in the tradition of provings (systematic observations of symptoms in healthy volunteers) and the law of similars, and is distinct from evidence-based pharmacological medicine. The claims made in classical homeopathic texts represent traditional practice, not established efficacy.

4. Key Constituents and Active Compounds

The Ranunculin–Protoanemonin–Anemonin Pathway

The chemistry of Ranunculus bulbosus is dominated by a cascade of interrelated lactone compounds that are unique to the family Ranunculaceae. Ranunculin, a glucoside, serves as a chemotaxonomic marker in Ranunculaceae plants. When these plants are damaged, an enzyme β-glucosidase triggers the conversion of ranunculin into protoanemonin through hydrolysis. Subsequently, protoanemonin undergoes cyclodimerization to form anemonin. The inherent instability of ranunculin and the rapid dimerization of protoanemonin render them unsuitable for use in biological assays.

Ranunculin concentrations in the fresh plant typically range from 0.1% to 1% of dry weight, with higher levels during flowering. Protoanemonin is unstable and can further dimerize to the less toxic anemonin, but its initial reactivity drives the plant's defensive toxicity.

This plant, like other buttercups, contains the toxic glycoside ranunculin, which gives it a bitter, acid taste, so cases of poisoning in humans are rare. It is also avoided by livestock when fresh, but when the plant dries the toxin is lost, so hay containing the plant is safe for animal consumption.

Anemonin

Anemonin is a dibutenolide natural product found in members of the buttercup family (Ranunculaceae) such as Helleborus niger, Ranunculus bulbosus, R. ficaria, R. sardous, R. sceleratus, and Clematis hirsutissima. Originally isolated in 1792 by M. Heyer, it is the dimerization product of the toxin protoanemonin. One of the likely active agents in plants used in Chinese medicine as an anti-inflammatory and in Native American medicine as a horse stimulant, its unique biological properties give it pharmaceutical potential as an anti-inflammatory agent.

Anemonin stands out as the optimal molecule for bioassays and demonstrates diverse biological properties, including anti-inflammatory, anti-infective, and anti-oxidant effects. Among these, anemonin exhibits the greatest promise in addressing arthritis, cerebral ischemia, and ulcerative colitis. Its potential medical uses are enhanced by its capacity to inhibit nitric oxide synthesis and successfully counteract lipopolysaccharide-induced inflammation.

In a 2018 analytical study comparing four Ranunculus species, the anemonin content of R. bulbosus, R. ficaria, R. sardous, and R. sceleratus was evaluated by TLC and HPLC, using hydroalcoholic (HA) and glycerol-ethanol (GE) extracts. In the aerial part of R. bulbosus, the anemonin content fell below the HPLC method's detection limit of 7.68 mg/ml. This finding indicates that R. bulbosus aerial parts have relatively low anemonin concentrations compared to some congeners such as R. sardous.

Other Phytochemicals

Numerous allelochemicals, including phenolics, flavonoids, alkaloids, saponins, fatty acids, organic acids, and essential oils, have been documented to be produced by Ranunculus species and may offer protection against chronic illnesses. Notably, numerous bioactive compounds such as flavonoids, triterpenes, saponins, alkaloids, and fatty acids have been isolated from this genus and investigated for their diverse pharmacological properties, including antioxidant, antitubercular, antimalarial, and immunomodulatory effects.

A 2012 phytochemical study specifically on R. bulbosus (Louaar et al., Chemistry of Natural Compounds, 48(1):166–167) identified secondary metabolites from this species. Anemonin, the dimer of protoanemonin, has antimicrobial, anti-inflammatory, and antimalarial activity, whereas (−)-ranunculin, a protoanemonin glycoside, possesses cytotoxicity and antimutagenic activity.

Additionally, upon drying, protoanemonin converts to anemonin, which further converts into anemonic acid by itself. Ranunculin, protoanemonin, and anemonin have medicinal properties, whereas anemonic acid does not.

5. Mechanisms of Action

Protoanemonin: Vesicant and Antimicrobial Mechanism

Protoanemonin is responsible for the burning hot taste and vesicant effect of Ranunculaceae plants. It possesses antibacterial, antifungal, cytotoxic, and antimutagenic activity, and its isolation, synthesis, and preparation as a therapeutically valuable medicinal product are well elaborated. By its marked inhibitory effects and its broad spectrum of activity against aerobes and anaerobes including multiresistant pathogenic strains, protoanemonin could be considered as a promising antimicrobial natural compound. Combinations of protoanemonin and antibiotics have also been investigated.

Protoanemonin, the lactone of γ-hydroxy-vinylacrylic acid, has in vitro activity against fungi. The MIC is 15 µg/ml, and RNA inhibition appears to be the first target of the drug. Structural analogies between protoanemonin and other cytotoxic unsaturated lactones, and the reversal by the amino acid cysteine of the antifungal action, suggest a possible mechanism of action.

Anemonin: Anti-inflammatory Mechanism

Anemonin exists in various Ranunculaceae and Gramineae plants, has a variety of biological activities such as antitumour, antibacterial, analgesic, and sedative properties. It can inhibit the release of IL-6 from mouse peritoneal macrophages induced by endotoxins, alleviate excessive inflammatory responses and systemic injury. Inhibition of nitric oxide production by LPS-induced endothelial cells has been shown to produce anti-inflammatory effects.

The two ranunculins, protoanemonin and anemonin, have shown fungicidal, antimicrobial, antimutagenic, and antipyretic properties, and have been used for ethnopharmacological purposes in many countries.

6. Scientific Evidence by Area of Use

6.1 Overall Evidence Status

There are no available high-quality clinical trials evaluating the use of bulbous buttercup for medicinal purposes. Uses described in the literature are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. The following subsections catalogue what evidence does exist, primarily for the plant's key constituents as studied in isolation or in closely related species, rather than for R. bulbosus itself.

6.2 Anti-inflammatory / Musculoskeletal (Arthritis, Pain)

Evidence level: Preclinical (in vitro and animal) only; no human clinical trials.

Anemonin — a constituent derivable from Ranunculaceae plants including R. bulbosus — demonstrates diverse biological properties, including anti-inflammatory effects. Among these, anemonin exhibits the greatest promise in addressing arthritis, cerebral ischemia, and ulcerative colitis. These findings are drawn from preclinical models and do not yet constitute clinical evidence of efficacy in humans.

6.3 Ulcerative Colitis (Gastrointestinal Inflammation)

Evidence level: Preclinical (animal and cell-line); no human clinical trials for R. bulbosus or its isolated constituents.

A 2022 study published in Chinese Medicine investigated the anti-inflammatory effects of anemonin in a mouse model of ulcerative colitis. C57BL/6 mice were administered dextran sulphate sodium (DSS; 3% [w/v]) to establish an animal model of UC. Mice were treated with an intraperitoneal injection of anemonin. Body weight and the disease activity index (DAI) were recorded. Haematoxylin and eosin staining, RT-qPCR, ELISA, and western blotting were performed to evaluate histopathological changes and tissue inflammation. HT-29 cells were treated with LPS and anemonin. Cell inflammation was evaluated using RT-qPCR and western blotting. The target proteins of anemonin were predicted using bioinformatics analysis and confirmed in vitro and in vivo. Anemonin improved DSS-induced body weight loss, shortened colon length, increased DAI, and induced pathological changes in the colon tissue of mice. These results are preclinical and cannot be extrapolated to human therapy.

6.4 Cerebral Ischemia / Neuroprotection

Evidence level: Preclinical (animal) only.

A study by Jia et al. (2014) in Journal of Molecular Neuroscience examined anemonin's ability to alleviate nerve injury after cerebral ischemia and reperfusion in rats by improving antioxidant activities and inhibiting the apoptosis pathway. These data come from a rodent model and have not been validated in human clinical trials.

6.5 Antimicrobial and Antifungal Activity

Evidence level: In vitro (laboratory) only; not tested clinically in humans.

Protoanemonin, a component of Ranunculus bulbosus, was tested as an antifungal agent on selected strains of dermatophytes and yeasts. The minimum inhibitory concentrations (MICs) ranged from 2.0 to 7.5×10⁻⁴ M and the minimum lethal concentrations from 3.8×10⁻⁴ M to >1.0×10⁻³ M. The most sensitive dermatophyte tested was Epidermophyton floccosum, and the most sensitive yeast was Rhodotorula glutinis.

The first report on the biological activity of anemonin was published in 1942 by Schmidt, who reported that aqueous solutions of 0.2% anemonin, and even further dilutions up to 1:12,500 and 1:25,000, were bacteriostatic and bactericidal for various pathogenic organisms, including diphtheria bacilli, staphylococci, and streptococci. Only later were the antimicrobial activities of anemonin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter cloacae, Staphylococcus aureus, and Micrococcus luteus tested. These remain in vitro findings.

6.6 Counterirritant / External Vesicant Application

Evidence level: Traditional and observational only; no controlled clinical trials.

Bulbous buttercup is very acrid, and application on the skin may cause blisters, swelling, and inflammation of surrounding skin and subcutaneous tissues. This vesicant property has been exploited historically in European folk medicine as a counterirritant, where deliberate blister formation was considered therapeutic. This practice carries significant risk and is not supported by modern clinical evidence.

6.7 Nitric Oxide Inhibition

Evidence level: In vitro; no human data.

Anemonin's potential medical uses are enhanced by its capacity to inhibit nitric oxide synthesis and successfully counteract lipopolysaccharide-induced inflammation. A study by Marrelli et al. (2021) published in Natural Product Research reported that Ranunculus species suppress nitric oxide production in LPS-stimulated RAW 264.7 macrophages; however, this is a cell-based result and has not been confirmed in human subjects.

7. Body Systems and Health Areas Associated with Bulbous Buttercup

Based on the historical record, phytochemical investigations, and preclinical research, the following body systems and health areas have been associated with Ranunculus bulbosus and its active constituents:

• Musculoskeletal system: Several Ranunculus species have been used in folk medicine to treat pain, gout, and rheumatism.
• Skin and dermatology: The plant was historically used externally to treat skin conditions like blisters, shingles, and corns.
• Gastrointestinal system: Anemonin is a natural molecule from the Ranunculaceae plants that exerts anti-inflammatory properties and has been studied in preclinical models of ulcerative colitis.
• Neurological system: Anemonin has been investigated for its ability to alleviate nerve injury after cerebral ischemia and reperfusion in rats.
• Immune/inflammatory pathways: Anemonin can inhibit the release of IL-6 from mouse peritoneal macrophages induced by endotoxins, alleviate excessive inflammatory responses, and has a good therapeutic effect on endotoxaemia in animal models.
• Respiratory system: In homeopathic tradition, the plant's medicinal properties are primarily associated with relieving respiratory and rheumatic symptoms.

8. Dosage Forms and Reported Dosages

There are no available high-quality clinical trials evaluating the use of bulbous buttercup for medicinal purposes, and therefore no scientifically established therapeutic dosages exist.

The following are dosage forms reported within the homeopathic literature and analytical research, presented descriptively without endorsement:

• Homeopathic potencies: The remedy is most often prescribed in the third to thirtieth potency for internal use, while mother tincture can be used for external application in cases of severe sciatica or delirium tremens.
• Preclinical research dosing (anemonin, animal models): In the DSS-induced ulcerative colitis mouse model, mice were treated with an intraperitoneal injection of anemonin. Specific milligram-per-kilogram dosages used in published preclinical studies are not standardized across publications and cannot be translated into human dosage guidance.
• In vitro antifungal concentrations (protoanemonin): The minimum inhibitory concentrations of protoanemonin against dermatophytes and yeasts ranged from 2.0 to 7.5×10⁻⁴ M, with minimum lethal concentrations from 3.8×10⁻⁴ M to >1.0×10⁻³ M — values established in laboratory testing only.
• Animal toxicity reference (protoanemonin): The LD₅₀ of protoanemonin in male Swiss albino mice was reported at 190 mg/kg.

9. Safety Considerations and Interactions

Toxicity of the Fresh Plant

Intoxications caused by Ranunculus are due mainly to the irritant effects of protoanemonin. Formed from glycosides such as ranunculin when plant tissues are macerated, protoanemonin is a potent vesicant that primarily irritates the mucous membranes of the digestive system. Effects on the urinary system, mammary glands, and brain associated with ingestion of especially large amounts of plant material have also been reported. Protoanemonin is subsequently polymerized to the inactive anemonin, the form found in dried plants.

When the leaves are crushed or bruised, ranunculin breaks down to form an acrid, toxic oil called protoanemonin. Contact with this oil causes dermatitis. Symptoms occur within an hour of contact and include burning and itching along with rashes and blisters. When the leaves are chewed, blisters can form on the lips and face. If swallowed, severe gastrointestinal irritation can follow, accompanied by dizziness, spasms, and paralysis.

Oral Ingestion

Taking bulbous buttercup by mouth may cause vomiting, diarrhea, blistering in the mouth, and abdominal pain. Protoanemonin, a constituent of bulbous buttercup, may also cause ventricular fibrillation (a heart rhythm disorder) and respiratory failure. Bulbous buttercup may also be toxic to the liver if taken by mouth (hepatotoxic), and may cause pleurodynia (pain in the chest).

Skin and Mucous Membrane Exposure

When Ranunculus plants are handled, naturally occurring ranunculin is broken down to form protoanemonin, which is known to cause contact dermatitis in humans; care should therefore be exercised in extensive handling of the plants.

Seasonal Variation in Toxicity

Ranunculus species vary in their levels of this toxic compound, and individual plants are said to be more toxic in the spring when they are actively growing and flowering. Protoanemonin breaks down further into an innocuous compound called anemonin, so dead and dried out plants are generally safe.

Veterinary and Livestock Toxicity

The toxin causes blistering and inflammation of skin and mucous membranes in affected animals, leading livestock like cows and horses to generally avoid the plant due to its bitter, pungent taste. In cases of forced consumption, such as during forage scarcity, symptoms include oral ulcers, gastrointestinal irritation, diarrhea, colic, and weight loss; severe intoxication in horses has been linked to abortions. A published veterinary case report (Swerczek T.W., JAVMA, 2016;248(6):669–72) documented abortions in Thoroughbred mares associated with consumption of Ranunculus bulbosus.

The bitter taste of protoanemonin can also be passed through the milk of lactating animals.

Allergy

Avoidance is indicated in individuals with a known allergy or hypersensitivity to bulbous buttercup (Ranunculus bulbosus).

Drug Interactions

There are currently a lack of high-quality studies on the medicinal applications of bulbous buttercup, and adverse effect information is based on traditional use and expert opinion — no specific drug interaction data from controlled studies has been identified in the peer-reviewed literature for R. bulbosus.

10. Summary of Evidence Strength

The Ranunculus species are poorly known as medicinal plants. They have potential toxicity given by the ranunculin and its enzymatic degradation compounds, protoanemonin and anemonin. Researchers have reported that Ranunculus extracts possess antioxidant, anti-inflammatory, antimutagenic, antimalarial, antibacterial, antitumoral, cardioprotective, and wound-healing properties, but the totality of this evidence is preclinical. There are no available high-quality clinical trials evaluating the use of bulbous buttercup for medicinal purposes. All reported biological activities are based on in vitro assays, animal experiments, or traditional use reports; no human randomized controlled trials, systematic reviews, or meta-analyses specific to R. bulbosus have been identified. Any therapeutic application therefore remains speculative and without an established evidence base.

References

• Sirak B. et al. "Ranunculin, Protoanemonin, and Anemonin: Pharmacological and Chemical Perspectives." Current Medicinal Chemistry, 2025. PubMed
• Aslam M. et al. "Therapeutic Potential of Ranunculus Species (Ranunculaceae): A Literature Review on Traditional Medicinal Herbs." PMC, 2022.
• Jiang L. et al. "Anti-inflammatory effects of anemonin on acute ulcerative colitis via targeted regulation of protein kinase C-θ." Chinese Medicine, 2022.
• Mares D. "Antimicrobial activity of protoanemonin, a lactone from ranunculaceous plants." Mycopathologia, 1987.
• Martín M.L. et al. "In vitro activity of protoanemonin, an antifungal agent." Planta Medica, 1990. PubMed.
• Neag T. et al. "The anemonin content of four different Ranunculus species." Pakistan Journal of Pharmaceutical Sciences, 2018. WHO/EMRO.
• Louaar S. et al. "Secondary metabolites of Ranunculus bulbosus." Chemistry of Natural Compounds, 2012.
• Cuny E. "Bioactive Ingredients of Helleborus niger L. (Christmas Rose): The Renaissance of an Old Medicinal Herb — A Review." Natural Product Communications, 2023.
• Wikipedia: Ranunculus bulbosus.
• Wikipedia: Anemonin.
• YourCareEverywhere / Krames: "Bulbous buttercup (Ranunculus bulbosus)."
• ScienceDirect Topics: Protoanemonin — overview.
• Cornell University Poisonous Plants: Ranunculosides / Ranunculins.
• Colorado State University Guide to Poisonous Plants: Ranunculus spp.
• Plants for a Future (PFAF): Ranunculus bulbosus.
• Clarke J.H. Materia Medica: Ranunculus Bulbosus. materiamedica.info.
• Awkward Botany: "Poisonous Plants: Buttercups," 2017.
• Grokipedia: Ranunculus bulbosus, 2026.